Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1)

Kuniko Sunami; Yoichi Naito; Eriko Aimono; Toraji Amano; Daisuke Ennishi; Hidenori Kage; Masashi Kanai; Keigo Komine; Takafumi Koyama; Takahiro Maeda; Sachi Morita; Daisuke Sakai; Shinji Kohsaka; Katsuya Tsuchihara; Takayuki Yoshino

doi:10.1007/s10147-021-01897-w

Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1)

Kuniko Sunami, Yoichi Naito, Eriko Aimono, Toraji Amano, Daisuke Ennishi, Hidenori Kage, Masashi Kanai, Keigo Komine, Takafumi Koyama, Takahiro Maeda, Sachi Morita, Daisuke Sakai, Shinji Kohsaka, Katsuya Tsuchihara, Takayuki Yoshino

岡山大学病院

研究成果 › 査読

抄録

The author wishes to update the original publication as follows: Under Results section of Abstract: The sentence starting with: “A total of…..” should read as: A total of 747 cases underwent CGP tests, 28 cases (3.7%) received genomically matched treatment, and 18 cases (2.4%) were referred for genetic counseling. In Results, under section: The performance of EPs at each core hospital: The sentence starting with: “Among the…” should read as: Among the 747 cases in core hospitals, 28 cases (3.7%, range 0–7.7%) received genomically matched treatments (Table 2); The sentence starting with: “Regarding the…” should read as: Regarding the germline findings, 18 of 747 cases (2.4%, range 0–15%) were referred for genetic counselling (Supplementary Table 2). In Table 4, the Recommended therapy for Site I should read as: Alpelisib, neratinib.

本文言語	English
ページ（範囲）	1007
ページ数	1
ジャーナル	International Journal of Clinical Oncology
巻	26
号	5
DOI	https://doi.org/10.1007/s10147-021-01897-w
出版ステータス	Published - 5月 2021

ASJC Scopus subject areas

外科
血液学
腫瘍学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1007/s10147-021-01897-w

他のファイルとリンク

フィンガープリント

「Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Sunami, K., Naito, Y., Aimono, E., Amano, T., Ennishi, D., Kage, H., Kanai, M., Komine, K., Koyama, T., Maeda, T., Morita, S., Sakai, D., Kohsaka, S., Tsuchihara, K., & Yoshino, T. (2021). Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1). International Journal of Clinical Oncology, 26(5), 1007. https://doi.org/10.1007/s10147-021-01897-w

Correction to : The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1). / Sunami, Kuniko; Naito, Yoichi; Aimono, Eriko その他.

In: International Journal of Clinical Oncology, Vol. 26, No. 5, 05.2021, p. 1007.

研究成果 › 査読

Sunami, K, Naito, Y, Aimono, E, Amano, T, Ennishi, D, Kage, H, Kanai, M, Komine, K, Koyama, T, Maeda, T, Morita, S, Sakai, D, Kohsaka, S, Tsuchihara, K & Yoshino, T 2021, 'Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1)', International Journal of Clinical Oncology, vol. 26, no. 5, pp. 1007. https://doi.org/10.1007/s10147-021-01897-w

Sunami K, Naito Y, Aimono E, Amano T, Ennishi D, Kage H その他. Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1). International Journal of Clinical Oncology. 2021 5月;26(5):1007. doi: 10.1007/s10147-021-01897-w

@article{bbc80d75bca14ffea18e9cfc6c5a7a33,

title = "Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1)",

abstract = "The author wishes to update the original publication as follows: Under Results section of Abstract: The sentence starting with: “A total of…..” should read as: A total of 747 cases underwent CGP tests, 28 cases (3.7%) received genomically matched treatment, and 18 cases (2.4%) were referred for genetic counseling. In Results, under section: The performance of EPs at each core hospital: The sentence starting with: “Among the…” should read as: Among the 747 cases in core hospitals, 28 cases (3.7%, range 0–7.7%) received genomically matched treatments (Table 2); The sentence starting with: “Regarding the…” should read as: Regarding the germline findings, 18 of 747 cases (2.4%, range 0–15%) were referred for genetic counselling (Supplementary Table 2). In Table 4, the Recommended therapy for Site I should read as: Alpelisib, neratinib.",

author = "Kuniko Sunami and Yoichi Naito and Eriko Aimono and Toraji Amano and Daisuke Ennishi and Hidenori Kage and Masashi Kanai and Keigo Komine and Takafumi Koyama and Takahiro Maeda and Sachi Morita and Daisuke Sakai and Shinji Kohsaka and Katsuya Tsuchihara and Takayuki Yoshino",

note = "Publisher Copyright: {\textcopyright} 2021, Japan Society of Clinical Oncology.",

year = "2021",

month = may,

doi = "10.1007/s10147-021-01897-w",

language = "English",

volume = "26",

pages = "1007",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Correction to

T2 - The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (International Journal of Clinical Oncology, (2021), 26, 3, (443-449), 10.1007/s10147-020-01844-1)

AU - Sunami, Kuniko

AU - Naito, Yoichi

AU - Aimono, Eriko

AU - Amano, Toraji

AU - Ennishi, Daisuke

AU - Kage, Hidenori

AU - Kanai, Masashi

AU - Komine, Keigo

AU - Koyama, Takafumi

AU - Maeda, Takahiro

AU - Morita, Sachi

AU - Sakai, Daisuke

AU - Kohsaka, Shinji

AU - Tsuchihara, Katsuya

AU - Yoshino, Takayuki

PY - 2021/5

Y1 - 2021/5

N2 - The author wishes to update the original publication as follows: Under Results section of Abstract: The sentence starting with: “A total of…..” should read as: A total of 747 cases underwent CGP tests, 28 cases (3.7%) received genomically matched treatment, and 18 cases (2.4%) were referred for genetic counseling. In Results, under section: The performance of EPs at each core hospital: The sentence starting with: “Among the…” should read as: Among the 747 cases in core hospitals, 28 cases (3.7%, range 0–7.7%) received genomically matched treatments (Table 2); The sentence starting with: “Regarding the…” should read as: Regarding the germline findings, 18 of 747 cases (2.4%, range 0–15%) were referred for genetic counselling (Supplementary Table 2). In Table 4, the Recommended therapy for Site I should read as: Alpelisib, neratinib.

AB - The author wishes to update the original publication as follows: Under Results section of Abstract: The sentence starting with: “A total of…..” should read as: A total of 747 cases underwent CGP tests, 28 cases (3.7%) received genomically matched treatment, and 18 cases (2.4%) were referred for genetic counseling. In Results, under section: The performance of EPs at each core hospital: The sentence starting with: “Among the…” should read as: Among the 747 cases in core hospitals, 28 cases (3.7%, range 0–7.7%) received genomically matched treatments (Table 2); The sentence starting with: “Regarding the…” should read as: Regarding the germline findings, 18 of 747 cases (2.4%, range 0–15%) were referred for genetic counselling (Supplementary Table 2). In Table 4, the Recommended therapy for Site I should read as: Alpelisib, neratinib.

UR - http://www.scopus.com/inward/record.url?scp=85103392542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103392542&partnerID=8YFLogxK

U2 - 10.1007/s10147-021-01897-w

DO - 10.1007/s10147-021-01897-w

M3 - Comment/debate

C2 - 33786712

AN - SCOPUS:85103392542

SN - 1341-9625

VL - 26

SP - 1007

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 5

ER -